• Skip to main content
  • Skip to header right navigation
  • Skip to site footer

Log in
  • Search
    • Search All SAGES Content
    • Search SAGES Guidelines
    • Search the Video Library
    • Search the Image Library
    • Search the Abstracts Archive
www.sages.org

SAGES

Reimagining surgical care for a healthier world

  • Home
    • Search
    • SAGES Home
    • SAGES Foundation Home
  • About
    • Awards
    • Who Is SAGES?
    • Leadership
    • Our Mission
    • Advocacy
    • Committees
      • SAGES Board of Governors
      • Officers and Representatives of the Society
      • Committee Chairs and Co-Chairs
      • Committee Rosters
      • SAGES Past Presidents
  • Meetings
    • SAGES NBT Innovation Weekend
    • SAGES Annual Meeting
      • 2026 Scientific Session Call for Abstracts
      • 2026 Emerging Technology Call for Abstracts
    • CME Claim Form
    • SAGES Past, Present, Future, and Related Meeting Information
    • SAGES Related Meetings & Events Calendar
  • Join SAGES!
    • Membership Application
    • Membership Benefits
    • Membership Types
      • Requirements and Applications for Active Membership in SAGES
      • Requirements and Applications for Affiliate Membership in SAGES
      • Requirements and Applications for Associate Active Membership in SAGES
      • Requirements and Applications for Candidate Membership in SAGES
      • Requirements and Applications for International Membership in SAGES
      • Requirements for Medical Student Membership
    • Member Spotlight
    • Give the Gift of SAGES Membership
  • Patients
    • Join the SAGES Patient Partner Network (PPN)
    • Patient Information Brochures
    • Healthy Sooner – Patient Information for Minimally Invasive Surgery
    • Choosing Wisely – An Initiative of the ABIM Foundation
    • All in the Recovery: Colorectal Cancer Alliance
    • Find A SAGES Surgeon
  • Publications
    • Sustainability in Surgical Practice
    • SAGES Stories Podcast
    • SAGES Clinical / Practice / Training Guidelines, Statements, and Standards of Practice
    • Patient Information Brochures
    • Patient Information From SAGES
    • TAVAC – Technology and Value Assessments
    • Surgical Endoscopy and Other Journal Information
    • SAGES Manuals
    • MesSAGES – The SAGES Newsletter
    • COVID-19 Archive
    • Troubleshooting Guides
  • Education
    • Wellness Resources – You Are Not Alone
    • Avoid Opiates After Surgery
    • SAGES Subscription Catalog
    • SAGES TV: Home of SAGES Surgical Videos
    • The SAGES Safe Cholecystectomy Program
    • Masters Program
    • Resident and Fellow Opportunities
      • SAGES Free Resident Webinar Series
      • Fluorescence-Guided Surgery Course for Fellows
      • Fellows’ Career Development Course
      • SAGES Robotics Residents and Fellows Courses
      • MIS Fellows Course
    • SAGES S.M.A.R.T. Enhanced Recovery Program
    • SAGES @ Cine-Med Products
      • SAGES Top 21 Minimally Invasive Procedures Every Practicing Surgeon Should Know
      • SAGES Pearls Step-by-Step
      • SAGES Flexible Endoscopy 101
    • SAGES OR SAFETY Video Activity
  • Opportunities
    • Fellowship Recognition Opportunities
    • SAGES Advanced Flexible Endoscopy Area of Concentrated Training (ACT) SEAL
    • Multi-Society Foregut Fellowship Certification
    • Research Opportunities
    • FLS
    • FES
    • FUSE
    • Jobs Board
    • SAGES Go Global: Global Affairs and Humanitarian Efforts
  • OWLS/FLS
You are here: Home / Abstracts / Evaluating the Impact of Opioid-Sparing Pain Management Agents in Laparoscopic Colorectal Surgery: Results from a National Sample

Evaluating the Impact of Opioid-Sparing Pain Management Agents in Laparoscopic Colorectal Surgery: Results from a National Sample

Deborah S Keller, MS, MD, Wissam Halabi, MD, Winston Chan, MD, Emily Saeler, MSN, RN, CRNI, James W Fleshman, MD, FACS, FASCRS, Walter Peters, MD, MBA, FACS, FASCRS. Baylor University Medical Center

Background: There is an opioid epidemic in the US, as pain medications given during the index stay serve as a gateway for chronic abuse. Efforts to reduce opioid use in surgery are paramount. The laparoscopic right hemicolectomy is one of the most common colorectal procedures performed, and a prime target for opioid-sparing pain management agents to improve outcomes. EXPAREL, a long-acting liposomal bupivacaine, is one tool that could help meet these needs by reducing opioid use, adverse events, and improving clinical recovery. Our goal was to look at the impact of EXPAREL in a national inpatient sample for patient and financial outcomes for a single procedure.

Methods: The Premier Perspectives Chargemaster Database was reviewed for patients undergoing laparoscopic right colectomy from 1/1/2011-9/31/2015. Patients were identified by ICD-9 primary procedure code(17.33), and stratified into EXPAREL(experimental) and control groups. Groups were 1:1 propensity-score matched on age, gender, comorbidity, region, payer, and hospital characteristics for comparability. The impact on perioperative and postoperative outcomes was evaluated. The main outcome measures were opioid use, opioid related adverse events(ORAE), length of stay(LOS) and total costs across groups.

Results: During the study period, 28,541 cases were identified; 8,805 at hospitals with EXPAREL available. Of these, 1,196(13.6%) were experimental and 7,603(86.4%) were controls. The experimental and control groups were well matched in patient and hospital demographics. After matching, there were 1,196 patients in each group. Operative times were comparable. The experimental group had significantly shorter PACU times(1.7 vs. 2.0 hours, p<0.001). Total opioid use for the hospital episode(459.0 vs. 482.4mg, p<0.001) and the rate of ORAE was significantly lower in the experimental group(5.5% vs. 8.4%, p=0.005). LOS was significantly shorter in the experimental than the control group(5.5 vs. 6.1 days, p<0.001). Despite the additional cost of the opioid-sparing agent, the total costs were slightly lower in the experimental group($14,834 vs. $14,952 respectively, p=NS). Postoperatively, readmissions at 60 and 90 days were significantly reduced in the experimental group(4.3% vs. 7.0%, p=0.004; 4.9% vs. 8.2%, respectively, p=0.001).

Conclusions: In a national sample, the single intervention of an opioid-sparing pain management agent was associated with a reduction in opioid use, complications, LOS, and readmissions. While total cost per patient was not significantly different, the cost savings over the population could be substantial with wider use of this agent. These results have implications for expanding use and controlled trials with this opioid-sparing pain management intervention to realize enhanced clinical and financial benefits.


Presented at the SAGES 2017 Annual Meeting in Houston, TX.

Abstract ID: 79459

Program Number: P006

Presentation Session: Poster of Distinction (Non CME)

Presentation Type: PDIST

198

Share this:

  • Click to share on X (Opens in new window) X
  • Click to share on X (Opens in new window) X
  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on LinkedIn (Opens in new window) LinkedIn
  • Click to share on Pinterest (Opens in new window) Pinterest
  • Click to share on WhatsApp (Opens in new window) WhatsApp
  • Click to share on Reddit (Opens in new window) Reddit
  • Click to share on Pocket (Opens in new window) Pocket
  • Click to share on Mastodon (Opens in new window) Mastodon

Related



Hours & Info

11300 West Olympic Blvd, Suite 600
Los Angeles, CA 90064

1-310-437-0544

[email protected]

Monday – Friday
8am to 5pm Pacific Time

Find Us Around the Web!

  • Bluesky
  • X
  • Instagram
  • Facebook
  • YouTube

Copyright © 2025 · SAGES · All Rights Reserved

Important Links

Healthy Sooner: Patient Information

SAGES Guidelines, Statements, & Standards of Practice

SAGES Manuals